We are thrilled to announce the launch of One Arcera, our transition towards a single organizational and operational structure that supports our vision to become a leading global life sciences company. One Arcera marks a significant step forward in our journey to boost growth, drive innovation and help address and mitigate the world’s healthcare challenges. By uniting our expertise, resources and talent, we are better positioned to deliver advanced solutions that truly make a difference. We are delighted to welcome new members to Arcera’s leadership team: Andrew Crossley as Chief Financial Officer, Erik Nordkamp as Chief Executive Officer of Arcera General Medicines, and Samir El Nasharty as Chief TechOps Officer. New leaders are joining a highly experienced and well-established Leadership Team led by Arcera Chief Executive Officer Isabel Afonso. (Arcera Leadership Team: https://lnkd.in/dw7Ycnc7) Our commitment to improving patient care remains stronger than ever. We are excited to embark on this new chapter with you our valued partners, stakeholders and community. Read more here: https://lnkd.in/dNXnhaZm Stay tuned for more updates as we move forward, together! #OneArcera #LifeSciences #SustainableGrowth #TogetherWeThrive
Arcera
Pharmaceutical Manufacturing
Connecting investments, talent and expertise to become a leader in addressing and mitigating healthcare challenges.
About us
Arcera is a global company in the life sciences sector that is headquartered in Abu Dhabi, United Arab Emirates. Our vision is to bridge investment, talent, and expertise to become a leader in addressing and mitigating healthcare challenges by offering products that improve the quality and longevity of human life while fostering sustainable growth. With an operational footprint spanning over 90 countries across four continents, we bring together complementary businesses offering 2,000 branded medicines across a wide range of therapeutic areas, supported by a combined workforce of more than 6,500 people. Our businesses: Acino International (Acino) is a pharmaceutical company headquartered in Switzerland with origins dating back to 1836 and manufacturing sites in five countries as well as commercial operations across four continents that develops, manufactures, markets, and distributes a wide range of medicines internationally. To learn more, visit https://acino.swiss Birgi Mefar Group (BMG) is one of Türkiye’s largest sterile production service companies specializing in the manufacturing of sterile injectables and glass packaging, in addition to pharmaceutical distribution services. To learn more, visit https://www.mefar.com Amoun Pharmaceutical Company (Amoun) is a leading pharmaceutical manufacturer headquartered in Egypt specialized in the development, manufacturing, marketing, distribution, and export of a wide range of human pharmaceutical and animal health products. To learn more, visit https://www.amoun.com Careers: Explore how you can contribute to making a difference in enabling longer and healthier lives while creating sustainable growth. Reach out to us at careers@arceralifesciences.com. Contact us: Collaboration lies at the heart of our business model and we actively seek partnerships to leverage the power of science to deliver impactful outcomes. Discover if you are the ideal partner by connecting with us at contact@arceralifesciences.com
- Website
-
www.arceralifesciences.com
External link for Arcera
- Industry
- Pharmaceutical Manufacturing
- Company size
- 5,001-10,000 employees
- Type
- Privately Held
- Founded
- 2024
Employees at Arcera
-
Isabel Afonso
-
Amin Ben Lakhal
Chief Legal Officer - Arcera
-
Ehab Nady
Senior Systems Analyst & Developer at ADQ, ARCERA, Amoun Pharmaceutical Company | Data Analytics | Technical Project Management | AUC Management…
-
Khaled Zaza
FP&A Director @ Arcera Lifesciences | ACCA, IFRS Diploma | Strategic Planning | Financial Reporting
Updates
-
M8 Pharmaceuticals, an Acino company, has signed an exclusive licensing and distribution agreement with LG Chem Ltd., a global company headquartered in South Korea that specializes in life sciences as one of its core businesses. Acino is part of Arcera, a global life sciences company headquartered in Abu Dhabi. Under this agreement, M8 Pharmaceuticals will market, commercialize and distribute Hyruan One® in Brazil, and Zemiglo® and Zemimet® SR (Zemiduo® SR in Mexico) in Mexico, Central America and the Dominican Republic. Zemimet® SR (Zemiduo® SR in Mexico) is an antidiabetic medication, while Hyruan One® is used to restore loss of viscoelasticity in joints caused by osteoarthritis. This strategic partnership aligns with M8 Pharmaceuticals’ mission to enhance the access to innovative and proven medicines across Latin America.
-
Allecra Therapeutics and Acino, part of Arcera, a global company in the life sciences sector headquartered in Abu Dhabi, have signed an exclusive licensing and supply agreement for Allecra Therapeutics’ novel antibiotic EXBLIFEP®, used for the treatment of severe infections, in the GCC and South Africa. The agreement with Allecra Therapeutics represents an important step in our strategy of becoming a leader in addressing and mitigating healthcare challenges through an extensive commercial organizational platform and our strong focus on patients’ needs.
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
arceralifesciences.com
-
Arcera is proud to be a part of Abu Dhabi Global Healthcare Week, a platform for open, inclusive exchange and collective action for a healthier world. Our participation aligns with our vision to connect investment, talent, and expertise to build transformative global businesses in the life sciences sector, with a focus on improving the quality and longevity of human life while fostering sustainable growth. Join us from May 13 to 15 and meet our Chief Executive Officer, Isabel Afonso, as we strive to anticipate the healthcare needs of tomorrow. #ADGHW #AbuDhabi #LifeSciences
-